In a dramatic shift in the way Americans approach everyday hygiene, scientists are urging a renewed focus on nasal care as a central component of personal wellness, and one product is taking the lead.

Emergent BioSolutions' strong Q2 2025 results and strategic turnaround signal robust growth potential and stock gains ahead.

L-lysine is an essential amino acid. Another amino acid, arginine, counteracts the antiviral action of lysine. As a result, L ...

Ethris begins patient dosing in phase 2a trial of lead mRNA candidate ETH47 for asthma: Munich, Germany Wednesday, August 6, 2025, 18:00 Hrs [IST] Ethris GmbH, a clinical-stage bi ...

Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that the first patient has been treated in a Phase 2a clinical trial inves ...

FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first ...

Life-saving nasal spray treatment for anaphylaxis now available in UK The first needle-free emergency treatment for anaphylaxis has been approved for use ...

The first needle-free emergency treatment for anaphylaxis - in the form of a nasal spray - will now be available in the UK.

Key Takeaways An insulin nasal spray might be a potential treatment for Alzheimer’s diseaseBrain scans show insulin travels to 11 key brain regions associated with memory and thoughtPeople with ...

A new nasal spray was developed at a Harvard University-affiliated hospital that appears to slow down the progression of Alzheimer's disease symptoms. "It can be given with other treatments," Dr ...

Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.

Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial ...